Figure 6.
Figure 6. HA-2-specific cytolytic activity of HA-2 TCR-modified T cells without HLA-A2 alloreactivity. PBMCs transduced with the different HA-2-TCR complexes were tested in a 51Cr-release assay against HLA-A2-positive HA-2-positive EBV-LCLs (EBV-RZ), HLA-A2-positive HA-2-negative EBV-LCLs (EBV-Z), EBV-Z loaded with the HA-2 peptide (EBV-Z + HA-2pep), HLA-A2-positive HA-2-positive CML cells (CML-T), HLA-A2-positive HA-2-negative CML cells (CML-Z), HLA-A2-negative HA-2-positive CML cells (CML-B), and HLA-A2-positive HFF fibroblast cells. As positive controls the original HA-2-specific T-cell clone HA2.27 and the allo-HLA-A2-specific T-cell clone MBM13 were used. The effector T cells were tested at an E/T ratio of 5:1 (HA-2.5 TCR-modified T cells, GFP/NGF-R-transduced T cells, HA-2.27 and MBM13) or 2:1 (HA-2.6 TCR-modified T cells) or 15:1 (HA-2.19 TCR-modified T cells). The cytotoxicity assay was performed for 18 hours.

HA-2-specific cytolytic activity of HA-2 TCR-modified T cells without HLA-A2 alloreactivity. PBMCs transduced with the different HA-2-TCR complexes were tested in a 51Cr-release assay against HLA-A2-positive HA-2-positive EBV-LCLs (EBV-RZ), HLA-A2-positive HA-2-negative EBV-LCLs (EBV-Z), EBV-Z loaded with the HA-2 peptide (EBV-Z + HA-2pep), HLA-A2-positive HA-2-positive CML cells (CML-T), HLA-A2-positive HA-2-negative CML cells (CML-Z), HLA-A2-negative HA-2-positive CML cells (CML-B), and HLA-A2-positive HFF fibroblast cells. As positive controls the original HA-2-specific T-cell clone HA2.27 and the allo-HLA-A2-specific T-cell clone MBM13 were used. The effector T cells were tested at an E/T ratio of 5:1 (HA-2.5 TCR-modified T cells, GFP/NGF-R-transduced T cells, HA-2.27 and MBM13) or 2:1 (HA-2.6 TCR-modified T cells) or 15:1 (HA-2.19 TCR-modified T cells). The cytotoxicity assay was performed for 18 hours.

Close Modal

or Create an Account

Close Modal
Close Modal